PLYMOUTH, Minn., April 20 /PRNewswire-FirstCall/ -- ev3 Inc. , a global medical device company focused on catheter-based technologies for the endovascular treatment of vascular diseases and disorders, announced today that it has priced its previously announced secondary offering at $19.00 per share. A total of 6,250,000 common shares are being sold by Warburg Pincus and The Vertical Group with an additional 2,500,000 common shares being offered by the company. Warburg Pincus has granted the underwriters an option to purchase up to an additional 1,312,500 shares of common stock to cover over-allotments, if any.
(Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGO)
The joint book-running managers for the offering are Banc of America Securities LLC, Piper Jaffray & Co. and J.P. Morgan Securities Inc., with Bear, Stearns & Co. Inc. and Thomas Weisel Partners LLC acting as co- managers.
A copy of the prospectus related to the offering may be obtained by contacting either: Banc of America Securities LLC, Capital Markets (Prospectus Fulfillment) by e-mail to dg.prospectus_distribution@bofasecurities.com or by mail to Banc of America Securities LLC, Capital Markets Operations, 100 West 33rd Street, 3rd Floor, New York, NY 10001; Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402; or J.P. Morgan Securities Inc., Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on April 19, 2007. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the securities under the securities laws of that state.
About ev3 Inc.
ev3 is a global medical device company focused on catheter-based technologies for the endovascular treatment of vascular diseases and disorders. For more information, please visit http://www.ev3.net.
Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties relate, but are not limited to, in no particular order: product demand and market acceptance, the impact of competitive products and pricing, and success of clinical testing. More detailed information on these and additional factors which could affect ev3 Inc.'s operating and financial results are described in the company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K. ev3 Inc. urges all interested parties to read this report to gain a better understanding of the many business and other risks that the company faces. Additionally, ev3 Inc. undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050615/CGEV3LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comev3 Inc.CONTACT: Patrick Spangler, CFO of ev3 Inc., +1-763-398-7000,pspangler@ev3.net; or Media, Laura Nobles of Nobles Communications,+1-310-795-0497, laura@noblescommunications.com, for ev3 Inc.; or Investor,Marian Briggs of Padilla Speer Beardsley, +1-612-455-1742,mbriggs@psbpr.com, for ev3 Inc.
Web site: http://www.ev3.net/
